Breast Cancer Treatment in Hyderabad

For average-risk women, mammographic screening typically begins at age 40 and continues every 1 to 2 years. If you have a family history of breast or ovarian cancer, especially before age 50, screening should start earlier — often a decade before the youngest affected relative's age at diagnosis. BRCA1 and BRCA2 mutations raise lifetime risk for both breast and ovarian cancer (and prostate cancer in men) — genetic counselling shapes surveillance for the whole family.

No. The majority of breast lumps are benign — most often fibroadenomas, cysts, or fibrocystic changes. However, any new, persistent, or changing lump should be evaluated by a doctor with a clinical breast exam and imaging, particularly in women over 35.

ER positive means the cancer cells have receptors for the hormone estrogen and grow in response to it. HER2 negative means the cancer does not over-express the HER2 protein. ER+/HER2- is the most common subtype (around 70% of cases) and typically responds well to hormonal therapy alongside surgery and, when needed, chemotherapy.

Yes — a second opinion is recommended, especially for newly diagnosed patients, for unusual or aggressive subtypes, or when recommendations seem unclear. In oncology, more than one defensible treatment path often exists. A second opinion confirms the plan or surfaces alternatives.

Triple negative breast cancer is a subtype where the cancer cells do not have estrogen receptors, progesterone receptors, or HER2 over-expression. It tends to be more aggressive and is treated primarily with chemotherapy, often combined with immunotherapy. Newer regimens have significantly improved outcomes.

Chemotherapy is not mandatory for every breast cancer. Subtype and stage decide whether chemo, hormonal therapy, targeted therapy, immunotherapy, surgery, or radiation come first — and in what order. Wrong sequence can close options that were open at diagnosis. Watch Dr. Danthala on 7TV, on ETV Sukhibhava (neoadjuvant), or see the media page.

Dr. Madhav Danthala consults at KIMS-Sunshine Hospitals, Begumpet (Room 545, 5th Floor OPD, Prakash Nagar 500003; Mon–Sat, 9 AM to 5 PM) and at Peoples Polyclinic, Manikonda (1st Floor, Sree Srinivasam Building 500089; Mon–Sat, 6 PM to 8 PM, prior appointment only). Begumpet appointments are booked online via KIMS Hospitals or KIMS Sunshine. For Manikonda evenings call Naresh on +91 80089 83828, or request a callback.

No. Chemotherapy is one option among several, and for a large share of ER-positive, HER2-negative, node-negative breast cancers it adds little over endocrine therapy alone — which is exactly what genomic recurrence-score assays are used to establish. Chemotherapy is close to routine in triple-negative disease and is usually paired with anti-HER2 therapy in HER2-positive disease. Subtype, stage and nodal status decide it; a diagnosis of breast cancer by itself does not. Dr. Madhav Danthala explains when chemotherapy is needed and why the order matters on 7TV Focus Health.

Giving chemotherapy before surgery (neoadjuvant therapy) does more than shrink a tumour. It makes breast conservation possible where mastectomy would otherwise be needed, it tests the cancer's response in real time, and in triple-negative and HER2-positive disease a residual cancer after neoadjuvant treatment triggers a change of adjuvant drug that would not have been available had surgery come first. Operating first can permanently close that information. Dr. Danthala discusses neoadjuvant therapy on ETV Sukhibhava and in First, Do Not Cut.

For early-stage disease, expect roughly six to twelve months of active treatment, then years of maintenance. Chemotherapy typically runs four to six months; surgery and recovery add three to six weeks; radiation is three to six weeks; anti-HER2 therapy continues to complete a year; endocrine therapy for ER-positive disease continues for five to ten years. The long tail is deliberate — most late recurrences in ER-positive breast cancer are prevented in years three to ten, not in the first six months.

Cost is driven by subtype far more than by hospital. Endocrine therapy for ER-positive disease is inexpensive; chemotherapy is moderate; anti-HER2 antibodies, CDK4/6 inhibitors, immunotherapy and antibody-drug conjugates are the expensive components, and biosimilars have reduced several of them substantially in India. Surgery, radiation, imaging and supportive care are relatively predictable. Ask for the plan to be costed by phase rather than as a single figure, and ask which components have biosimilar or patient-assistance options — for most families that conversation moves the number more than choosing a different hospital does.